清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Chimeric antigen receptor T cell therapy in autoimmune neurological disease: current status of efficacy and safety

作者
Peter Bradhurst,Todd A. Hardy,Sean Riminton
出处
期刊:BMJ Neurology Open [BMJ]
卷期号:8 (2): e001611-e001611
标识
DOI:10.1136/bmjno-2026-001611
摘要

Autoimmune neurological diseases affecting the central nervous system, peripheral nervous system and neuromuscular junction are frequently refractory to conventional B-cell-depleting therapies such as CD20-directed monoclonal antibodies, highlighting a need for more effective treatment approaches. Chimeric antigen receptor T (CAR-T) cell therapy, initially developed for haematological malignancy, has been repurposed to more comprehensively deplete pathogenic B-cell and plasma cell populations in autoimmune disease, raising the possibility of durable, treatment-free remission. This scoping review, conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-ScR guidelines, examined published clinical studies from January 2023 to January 2026 in which CAR-T cells targeting CD19, CD20 or B-cell maturation antigen were used to treat autoimmune neurological disease, identifying 19 eligible studies. Efficacy signals were most consistent in refractory acetylcholine receptor antibody-positive generalised myasthenia gravis and Aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, with encouraging but more preliminary results reported in multiple sclerosis, Lambert-Eaton myasthenic syndrome, myelin oligodendrocyte glycoprotein antibody-associated disease, chronic inflammatory demyelinating polyneuropathy, stiff-person syndrome and autoimmune encephalitis. Relapse was reported across several conditions, with follow-up generally limited to under two years. The safety profile compared favourably with that seen in oncological CAR-T use, with lower rates of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, although cytopenias, infection and prolonged hypogammaglobulinaemia remain clinically significant, and local immune effector cell-associated toxicity syndrome is an emerging concern not yet formally reported in this population. Current evidence remains limited to small, largely uncontrolled studies with heterogeneous outcome reporting. Adequately powered, longer-term controlled trials are needed before CAR-T therapy can be recommended more broadly in the management of refractory autoimmune neurological disease.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
bao完成签到,获得积分10
1秒前
小冯完成签到,获得积分10
5秒前
fomo完成签到,获得积分0
6秒前
坦率钢笔完成签到,获得积分10
7秒前
yuan完成签到,获得积分10
8秒前
精明开山完成签到,获得积分10
11秒前
刘沂卓完成签到,获得积分10
13秒前
suda完成签到,获得积分10
17秒前
怡然的千儿完成签到,获得积分10
20秒前
MIO完成签到,获得积分10
22秒前
美满的水卉完成签到,获得积分10
22秒前
是丹小朱呀完成签到,获得积分10
23秒前
夏月虚闲完成签到,获得积分10
24秒前
yuxuan1完成签到,获得积分10
25秒前
yuxuan完成签到,获得积分10
29秒前
cxf完成签到,获得积分10
32秒前
Asumita完成签到,获得积分10
38秒前
啵啵椰完成签到,获得积分10
50秒前
简单代梅完成签到,获得积分10
1分钟前
1分钟前
顺利的雅旋完成签到,获得积分10
1分钟前
善良的金鱼完成签到,获得积分10
1分钟前
初景发布了新的文献求助10
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
高高仙人掌完成签到,获得积分10
1分钟前
殷勤的半凡完成签到,获得积分10
1分钟前
安详的老五完成签到,获得积分10
1分钟前
火星上的笑寒完成签到,获得积分10
2分钟前
ding的应助被amiee采纳,获得10
2分钟前
含蓄的新柔完成签到,获得积分10
2分钟前
dianeil发布了新的文献求助10
2分钟前
2分钟前
amiee发布了新的文献求助10
2分钟前
somehgo的应助被betsydouglas14采纳,获得30
3分钟前
共享精神的应助被ping采纳,获得10
3分钟前
包容的初阳完成签到,获得积分10
3分钟前
3分钟前
激动的忆翠完成签到,获得积分10
3分钟前
风趣馒头完成签到,获得积分10
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185411
求助须知:如何正确求助?哪些是违规求助? 9574140
关于积分的说明 21834375
捐赠科研通 7782865
什么是DOI,文献DOI怎么找? 3434552
关于科研通互助平台的介绍 2558842
邀请新用户注册赠送积分活动 2481280